Answers are grounded in this paper and cite their sources.
Randomized rater-blinded trial reports noninferior remission from BDNF methylation-guided therapy in major depression, suggesting fewer adverse events.
Brain-derived neurotrophic factor (BDNF) is essential for antidepressant treatment of major depressive disorder (MDD). Our repeated studies suggest that DNA methylation of a specific CpG site in the promoter region of exon IV of the BDNF gene (CpG -87) might be predictive of the efficacy of monoaminergic antidepressants such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and others. This trial aims to evaluate whether knowing the biomarker is non-inferior to treatment-as-usual (TAU) regarding remission rates while exhibiting significantly fewer adverse events (AE).
No takes yet. Share an insight, caveat, or question.
Maier et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: